Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Market Forecast: Pancreatic Ductal Adenocarcinoma – Pipeline Review, H2 2016

Thursday, November 10, 2016 5:13
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary:

WiseGuy Report’s latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Ductal Adenocarcinoma – Pipeline Review, H2 2016, provides an overview of the Pancreatic Ductal Adenocarcinoma (Oncology) pipeline landscape.

Pancreatic ductal adenocarcinoma is a malignant neoplasm that affects pancreas. Symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression, blood clots. Predisposing factors include smoking, alcohol abuse, obesity, family history, age, chronic pancreatitis and diabetes. Treatment includes chemotherapy and radiation therapy.

Get Sample Report@ https://www.wiseguyreports.com/sample-request/731517-pancreatic-ductal-adenocarcinoma-pipeline-review-h2-2016

Report Highlights

WiseGuy Report’s Pharmaceutical and Healthcare latest pipeline guide Pancreatic Ductal Adenocarcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 15, 1 and 15 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Pancreatic Ductal Adenocarcinoma.

Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Leave an Enquiry@ https://www.wiseguyreports.com/enquiry/731517-pancreatic-ductal-adenocarcinoma-pipeline-review-h2-2016

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content:

Table of Contents 2
Introduction 5
Pancreatic Ductal Adenocarcinoma Overview 6
Therapeutics Development 7
Pancreatic Ductal Adenocarcinoma – Therapeutics under Development by Companies 9
Pancreatic Ductal Adenocarcinoma – Therapeutics under Investigation by Universities/Institutes 11
Pancreatic Ductal Adenocarcinoma – Pipeline Products Glance 12
Pancreatic Ductal Adenocarcinoma – Products under Development by Companies 15
Pancreatic Ductal Adenocarcinoma – Products under Investigation by Universities/Institutes 18
Pancreatic Ductal Adenocarcinoma – Companies Involved in Therapeutics Development 19
Pancreatic Ductal Adenocarcinoma – Therapeutics Assessment 52
Drug Profiles 65
Pancreatic Ductal Adenocarcinoma – Dormant Projects 234
Pancreatic Ductal Adenocarcinoma – Discontinued Products 235
Pancreatic Ductal Adenocarcinoma – Product Development Milestones 236
Appendix 243

List of Tables 
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016 13
Number of Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Pancreatic Ductal Adenocarcinoma – Pipeline by BerGenBio AS, H2 2016 25
Pancreatic Ductal Adenocarcinoma – Pipeline by BioNTech AG, H2 2016 26   Continued…..

List of Figures 
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016 13
Number of Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Assessment by Monotherapy Products, H2 2016 58
Number of Products by Top 10 Targets, H2 2016 60
Number of Products by Stage and Top 10 Targets, H2 2016 60
Number of Products by Top 10 Mechanism of Actions, H2 2016 63
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 63
Number of Products by Routes of Administration, H2 2016 67
Number of Products by Stage and Routes of Administration, H2 2016 67
Number of Products by Top 10 Molecule Types, H2 2016 69
Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

For more information or any query mail at sales@wiseguyreports.com

—-

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent  

WISE GUY RESEARCH CONSULTANTS PVT LTD

75 Arlington Street, Suite 500,

Boston, Massaachusetts – 02116

United States of America                                                                                                                           

+1 646 845 9349 / +44 208 133 9349                                                       

https://www.wiseguyreports.com/

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.